Radiofrequency catheter ablation of premature ventricular complexes from right ventricular outflow tract improves left ventricular dilation and clinical status in patients without structural heart disease  by Takemoto, Masao et al.
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PHeart Rhythm Disorders
adiofrequency Catheter Ablation
f Premature Ventricular Complexes From
ight Ventricular Outflow Tract Improves
eft Ventricular Dilation and Clinical
tatus in Patients Without Structural Heart Disease
asao Takemoto, MD, Hitoshi Yoshimura, MD, Yurika Ohba, MD, Yasuharu Matsumoto, MD,
mpei Yamamoto, MD, Masahiro Mohri, MD, Hideo Yamamoto, MD, Hideki Origuchi, MD
itakyushu, Japan
OBJECTIVES The present study evaluated clinical benefits of radiofrequency catheter ablation (RFA) for
premature ventricular complexes from right ventricular outflow tract (RVOT-PVC) in
patients without structural heart disease.
BACKGROUND It is unknown whether PVC causes left ventricular (LV) dilation, which is a well-recognized
precursor of LV dysfunction and heart failure, and whether eliminating PVC by RFA
produces clinical benefits in patients with RVOT-PVC.
METHODS Frequency of PVC per total heart beats by 24-h Holter monitoring, left ventricular ejection
fraction (LVEF), left ventricular end-diastolic internal dimension (LVDd), mitral regurgi-
tation (MR) by echocardiogram, cardiothoracic ratio (CTR) by chest radiogram, and New
York Heart Association (NYHA) functional class of 40 patients with RVOT-PVC without
structural heart disease were evaluated before and 6 to 12 months after RFA.
RESULTS Before RFA, a subgroup of patients with frequent (20%) PVC demonstrated significantly
enlarged LVDd and CTR, reduced LVEF, increased MR, and deteriorated NYHA
functional class as compared to the subgroup with rare (20%) PVC (54  1 mm vs. 45 
1 mm, 52  2% vs. 46  1%, 66  2% vs. 73  2%, 1.2  0.2 degree vs. 0.4  0.1 degree,
and 1.8  0.2 vs. 1.3  0.1, respectively; p  0.05). Furthermore, ablating RVOT-PVC
readily produced the improvement of all these abnormalities (47 1 mm, 41 1%, 72 2%,
0.3  0.1 degree, and 1.0  0.0, respectively; p  0.05 compared with before RFA).
CONCLUSIONS These findings suggest that frequent (20%) RVOT-PVC may be a possible cause of LV
dysfunction and/or heart failure, and RFA produces clinical benefits in these
patients. (J Am Coll Cardiol 2005;45:1259–65) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.12.073Cardiology Foundation
r
t
w
h
P
p
M
S
2
m
0
o
h
w
g
M
(
asolated premature ventricular complexes (PVC) are the
ost common arrhythmias observed in patients without
tructural heart disease (1). It has been recently reported
hat frequent PVC caused left ventricular (LV) dysfunction
hat can be reversed by suppression of PVC with antiar-
hythmic agents (2,3) or radiofrequency catheter ablation
RFA) (4,5) in patients with dilated cardiomyopathy. It is
See page 1266
ncertain, however, whether frequent PVC causes LV
ilation and dysfunction even in patients with no evidence
f structural heart disease and, if so, whether suppression of
VC improves these changes. In recent years, RFA has
roven to be a safe and successful therapy for arrhythmias
6,7). The purpose of this study was two-fold: 1) to examine
hether frequent premature ventricular complexes from
From Internal Medicine, Kyushu Kosei-Nenkin Hospital, Kitakyushu, Japan.a
Manuscript received October 9, 2004; revised manuscript received December 2,
004, accepted December 6, 2004.ight ventricular outflow tract (RVOT-PVC) without struc-
ural heart disease may cause LV dilation, which is a
ell-recognized precursor of LV dysfunction and congestive
eart failure (8); 2) to evaluate the role of ablating RVOT-
VC per RFA on cardiac function in patients with de-
ressed cardiac function.
ETHODS
tudy population and laboratory analysis. From 1994 to
004, 45 consecutive patients (10 males and 35 females with
ean age of 50  2 years and body surface area of 1.57 
.02 m2) with monomorphic RVOT-PVC and no evidence
f underlying structural heart disease underwent RFA at our
ospital. All patients had their history recorded, and under-
ent physical examination, laboratory analysis, chest radio-
ram, 12-lead electrocardiogram, 24-h Holter monitoring,
-mode, two-dimensional, and Doppler echocardiogram
SONOS 2000, Hewlett-Packard, San Diego, California,
nd SEQUOIA 512, Siemens, Erlangen, Germany) on
dmission or within at least 1 month before admission, and
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LV Function Benefits of RFA of RVOT-PVC April 19, 2005:1259–65to 12 months after RFA (average 8 1 month). The 24-h
olter monitoring and echocardiogram were performed on
he same day. All patients also took routine echocardiogram
n the next day of RFA to evaluate the possible procedure-
elated complications. We evaluated the chamber size of LV
nd right ventricle (RV), and degree of mitral regurgitation
t parasternal long-axis or apical four-chamber view, respec-
ively. Left ventricular ejection fraction (LVEF) was calcu-
ated by the Teichholz method. All values of echocardio-
ram were recorded during sinus rhythm, but not at the
VC beat, nor at the post-PVC beat. All patients also
nderwent the exercise electrocardiogram testing, cardiac
atheterization with coronary angiography, and/or 201-
hallium scintigraphy. These examinations yielded no evi-
ence of clinically overt structural heart disease, including
oronary artery disease, valvular heart disease, congenital
eart disease, LV hypertrophy, and RV abnormalities in all
atients. Brain natriuretic peptide of five recent patients was
valuated on admission and six months after RFA.
efinition of RVOT-PVC. Right ventricular outflow
ract-PVC was defined as a characteristic electrocardio-
raphic appearance of a left bundle branch block (LBBB)
ontour in V1 and an inferior axis in the frontal plane.
entricular tachycardia was defined with standard electro-
ardiographic criteria of at least five consecutive PVC at a
ate 120 beats/min. Patients with ventricular tachycardia
nd atrial tachyarrhythmia including atrial fibrillation, atrial
utter, atrial tachycardia, and paroxysmal supraventricular
achycardia were excluded in this study because they may
ause tachycardia-induced LV dilation (9,10). The region of
he LV outflow tract was not an origin of PVC of all
atients in this study.
apping and catheter ablation procedure. All procedures
ere performed after written informed consent was ob-
ained. The patients were studied in the fasting state
ithout sedation. Antiarrhythmic drugs were discontinued
or at least six half-lives before the procedure. Under local
nesthesia, a 7-F deflectable quadripolar ablation catheter
Boston Scientific EP Technologies, Natick, Massachusetts)
ith a 4-mm-tip electrode was introduced percutaneously
nto the RV. Based on the 12-surface-lead electrocardio-
ram with spontaneous RVOT-PVC, pace mapping was
Abbreviations and Acronyms
LBBB  left bundle branch block
LV  left ventricle/ventricular
LVDd  left ventricular end-diastolic internal dimension
LVDs  left ventricular end-systolic internal dimension
LVEF  left ventricular ejection fraction
NYHA  New York Heart Association
PVC  premature ventricular complexes
RFA  radiofrequency catheter ablation
RV  right ventricle/ventricular
RVOT  right ventricular outflow tract
%PVC  frequency of premature ventricular complexesone by using bipolar pacing between the distal pair of the 4lectrodes with a stimulation pulse width of 2 ms. If the
ulprit PVC were not found during the procedure, isopro-
erenol administration and/or programmed electrical stim-
lation with digital stimulator (Cardiac Stimulator, Nihon
ohden Co., Tokyo, Japan) was performed to induce the
ulprit PVC as previously described (6). An optimal pace
ap was defined as a match of all 12 surface leads by
omparing the R/S ratio and subtle notching in the QRS
omplex during pacing. An identical match was necessary in
t least 11 of 12 leads. The RFA was performed based on an
ptimal pace map for 60 to 90 s with a preset temperature
f 50 to 60°C and a power limit of 50 W. A successful
blation was defined as the no recurrence and non-
nducibility of culprit PVC with and without isoproterenol
dministration at the rate of 0.2 to 0.6 g/min and/or
rogrammed electrical stimulation during at least 30 min
fter ablation. All 12 surface electrocardiograms and the
ipolar intracardiac electrograms (filtered at 30 to 400 Hz)
ere recorded and stored by using a 48-channel acquisition
ystem (CardioLabEP, Prucka Engineering Inc., Houston,
exas). During the procedure, intravenous heparin was
iven as a 100 IU/kg bolus dose followed by boluses of
,000 IU every hour. All patients received oral antiplatelets
or eight weeks after RFA, but no antiarrhythmic drugs.
rocedural success was defined as no recurrence of culprit
VC within 72 h after procedure under electrocardiogram
onitoring.
tatistical analysis. Numerical results are expressed in the
ext as the mean  standard deviation. Paired data were
ompared by Student t tests. The differences between the
ontinuous variables before and 1 day or 6 to 12 months after
FA in each group, or between the lower, middle, and upper
roup in each period, were compared by using a repeated-
easures analysis of variance followed by Bonferroni’s test for
ultiple comparisons. Correlation between the two parameters
as determined by simple linear regression analysis. A p 
.05 was considered to indicate statistical significance.
ESULTS
atient characteristics. An RFA procedure for RVOT-
VC was performed in 45 patients. Because five patients
11%) were lost to follow-up, they were excluded from the
tatistical analysis. Procedural success was achieved in 37
93%) of the patients. One patient (3%) suffered from a
rocedure-related complication with femoral arteriovenous
stula. During follow-up, recurrence of culprit RVOT-
VC was observed in one patient (3%), who underwent
epeated RFA with successful result. Relationships between
he left ventricular end-diastolic internal dimension
LVDd) and the frequency of PVC (%PVC) by 24-h Holter
onitoring of 40 patients before RFA were examined
Fig. 1). The %PVC was calculated as: 100·[number of
VC/number of total heart beats per 24 h]. A significant
orrelation was found between the LVDd and %PVC (y 
5.8 0.254x, r 0.56, p 0.01), indicating that frequent
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April 19, 2005:1259–65 LV Function Benefits of RFA of RVOT-PVCVC might cause LV dilation. Patients (n  40) were
ivided into three groups (the lower [10%; n  14],
iddle [10% to 20%; n  12], and upper [20%; n  14]
roup) according to the tertiles of %PVC. Baseline charac-
eristics of the patients are shown in Table 1. There was no
tatistical difference in body surface area, hemodynamic
ariables including systolic and diastolic blood pressure and
esting heart rate, or the prevalence of diabetes (7%, 8%, and
%, respectively) or hypertension (21%, 16%, and 21%,
espectively) between the three groups. The mean patients’
ge was slightly older in the middle and upper groups than
he lower group, but the differences were not significant
etween the three groups. Symptom duration was signifi-
antly shorter in the middle and upper groups compared
ith the lower group (p  0.05 and 0.05, respectively). No
atients had chronic obstructive pulmonary disease, renal
ysfunction (serum creatinine more than 1.5 mg/dl), liver
isease (liver enzyme values in excess of 2  normal), or
nderlying malignant disease.
4-h Holter monitoring. Table 2 summarizes analysis of
4-h Holter monitoring. The number of total heart beats
as not statistically different before or after RFA between
he three groups. However, RFA produced a significant
igure 1. Scatter plots showing the relationship between the left ventric-
lar end-diastolic internal dimension (LVDd) and frequency of premature
entricular complex (%PVC) (n  40).
Table 1. Patients’ Characteristics
Group
Number of patients (40 patients)
Successful ablation (37 patients; 93%)
Male:female (8:32)
Age (yrs)
Body surface area (m2) 1
Symptom duration (months)
Hemodynamic variables on admission
Systolic BP (mm Hg) 1
Diastolic BP (mm Hg)
Resting heart rate (beats/min)
Hypertension
Diabetes mellitus*p  0.05 versus the lower group.
BP  blood pressure.ecrease in the number of total heart beats in the upper
roup (p  0.05), but not in the lower or middle groups.
adiofrequency ablation significantly reduced the number
f total PVC (p  0.01 for all conditions) and %PVC (p 
.01 for all conditions) with no evidence of the recurrence of
ulprit PVC in all three groups. There was no statistical
ifference of the number of total PVC and %PVC after
FA between the three groups. There was no statistical
ifference in the frequency of premature atrial complexes
efore and after RFA between the three groups (data not
hown).
chocardiogram and chest radiography. Figure 2 summa-
izes the results of the analysis of echocardiograms (Figs. 2A to
E) and chest radiograms (Fig. 2F). Before RFA, a sub-
roup of patients in the upper group demonstrated signifi-
antly reduced LVEF, enlarged LVDd, and left ventricular
nd-systolic internal dimension (LVDs), and increased
egree of mitral regurgitation and cardiothoracic ratio
ompared with the lower or middle groups (p  0.05 and
.05, respectively) (Figs. 2A to 2D and 2F). There was no
tatistical difference in these parameters between the lower
nd middle groups. The examination by echocardiogram
ne day after RFA revealed the same results as those before
FA. However, at the examination 6 to 12 months after
FA, all of these abnormalities seen in the upper group
efore RFA were completely reversed (Figs. 2A to 2D and
F), and there was no statistical difference in these param-
ters between the three groups. There was no statistical
ifference in these parameters during follow-up in the lower
r middle groups. There was no evidence of RV abnormal-
ties in all patients (Fig. 2E), indicating that arrhythmogenic
V cardiomyopathy was unlikely. There was no statistical
ifference in any of the analyzed parameters between the
roups before and after RFA.
ew York Heart Association (NYHA) functional class
nd serum brain natriuretic peptide concentration. The
YHA functional class was evaluated in all patients on
dmission and 6 to 12 months after RFA. Before ablation,
YHA functional class was demonstrated to be significantly
er
%)
Middle
(10%–20%)
Upper
(>20%)
12 14
0%) 10 (83%) 13 (93%)
1 4:8 1:13
3 54  4 52  4
0.04 1.55  0.03 1.56  0.03
9 12  5* 15  7*
5 124  5 119  4
3 69  2 66  2
4 71  4 77  3
%) 2 (16%) 3 (21%)
) 1 (8%) 1 (7%)Low
(<10
14
14 (10
3:1
46 
.64 
46 
20 
69 
70 
3 (21
1 (7%
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LV Function Benefits of RFA of RVOT-PVC April 19, 2005:1259–65orse in accordance with %PVC (p  0.05) (Fig. 3).
adiofrequency ablation significantly improved NYHA
unctional class in each group compared with before inter-
ention. The serum brain natriuretic peptide concentration
f five recent patients was evaluated; one in the lower group,
ne in the middle group, and three in the upper group,
espectively. The serum brain natriuretic peptide level in the
pper group was elevated to 56  3 pg/dl before RFA.
owever, it significantly decreased to 3.7  0.3 pg/dl six
onths after RFA (p  0.01). The value of two patients in
he lower and middle groups did not elevate before and after
FA (data not shown).
igure 2. The analysis of left ventricular ejection fraction (LVEF) (A), left
entricular end-diastolic internal dimension (LVDd) (B), left ventricular
nd-systolic internal dimension (LVDs) (C), degree of mitral regurgitation
MR) (D), and right ventricular internal dimension (RVD) (E) by
chocardiogram, and cardiothoracic ratio (CTR) (F) by chest radiography
efore (dotted bars) and 1 day (gray bars) or 6 to 12 months after (solid
ars) radiofrequency catheter ablation (RFA). Before RFA and one day
fter RFA, a subgroup of patients with frequent (20%) premature
entricular complexes (PVC) demonstrated significantly reduced LVEF,
nlarged LVDd and LVDs, and increased MR and CTR as compared to
he subgroup with rare (20%) PVC. However, all of these abnormalities
een in the upper group before RFA were completely reversed 6 to 12
onths after RFA. There was no evidence of right ventricular abnormal-
ties in any patient. *p  0.05 versus before and one day after RFA in each
Table 2. 24-h Holter Monitoring Analysis in P
Group
Low
(<1
Number of patients 1
Before RFA
Total HB ( 103 beats/day) 105 
Total PVC ( 102 beats/day) 46 
%PVC (%) 4 
After RFA
Total HB ( 103 beats/day) 103 
Total PVC ( 102 beats/day) 0.5 
%PVC (%) 0.05 
*p  0.01 versus the lower group; †p  0.01 versus the midd
HB  heart beats; PVC  premature ventricular comple
of PVC.roup; †p  0.05 versus the lower and middle groups in each period.
alues are mean  SD.
*
tatients symptoms and medications. On admission, all
atients had PVC-associated symptoms (Table 3). Of 40
atients, 26 patients (65%) had been taking antiarrhythmic
gents before admission, such as beta-blocker, bepridil, class
a, Ib, and/or Ic agents of Vaughan Williams classification
Table 3). However, these agents were not sufficiently effective
o eliminate PVC-associated symptoms. No patients had
een on amiodarone or sotalol. All of the patients with
uccessful procedure reported the absence of PVC-
ssociated symptoms and could discontinue antiarrhythmic
gents after RFA. The antihypertensive or antidiabetic
gents, such as beta-blockers, calcium-channel blockers,
ngiotensin-converting enzyme inhibitors, or sulfonylurea,
ere continued in patients with hypertension or diabetes
efore and after RFA.
utcome of patients with unsuccessful RFA. Of 40
atients, three patients were procedurally unsuccessful in
his study; one in the upper group, and two in the middle
roup. Table 4 summarizes the results of the analysis of
chocardiograms, chest radiograms, and NYHA functional
lass of these patients. All three patients took medications,
hich seemed to be partially effective in the patient in the
pper group. All of these factors in two patients of the
iddle group did not further deteriorate during follow-up.
igure 3. The analysis of New York Heart Association (NYHA) func-
ional class before (dotted bars) and 6 to 12 months after (solid bars)
adiofrequency catheter ablation (RFA). Before ablation, NYHA func-
ional class was significantly worse in accordance with frequency of
remature ventricular complex (%PVC); RFA significantly improved
YHA functional class in each group compared with before intervention.
nts With Successful Procedure
Middle
(10%–20%)
Upper
(>20%)
10 13
105  4 113  4
133  11* 381  34*†
13  1* 34  3*†
104  4 98  5‡
11  8‡ 13  9‡
‡ 1.9  1.0‡ 1.3  0.9‡
p; ‡p  0.01 versus before radiofrequency catheter ablation.
A  radiofrequency catheter ablation; %PVC  frequencyatie
er
0%)
4
4
9
1
5
0.3‡
0.04
le grou*p  0.01, *p  0.05 versus before RFA in each group. †p  0.05 versus
he lower and middle groups in each period. Values are mean  SD.
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April 19, 2005:1259–65 LV Function Benefits of RFA of RVOT-PVCnterestingly, the LVDd, LVDs, LVEF, degree of mitral
egurgitation by echocardiogram, and cardiothoracic ratio
y chest radiogram of the patient with unsuccessful RFA in
he upper group still deteriorated during follow-up.
ISCUSSION
solated PVC are the most common arrhythmia that phy-
icians often see during patient examination (1). The pres-
nce of PVC has been found to be an independent risk
actor for sudden death (11), especially in patients after
yocardial infarction (12,13). Many patients with PVC
ften experience disabling symptoms and sometimes need
ong-term antiarrhythmic medications. However, the latter
re often ineffective and may have adverse effects, such as
he increasing mortality, probably due to their proarrhyth-
ic effects, even though markedly suppressing the occur-
ence of PVC (14–16). It has been reported that RFA
roduces clinical benefits to the patients with ventricular
achycardia (6,7,17), and some case reports have shown that
he dilated cardiomyopathy patients with PVC-depressed
ardiac function and successful RFA of these arrhythmias
Table 3. Patients Symptoms and Medications
Group
Lower
(<10%; n  14
Symptoms
Palpitation 6 (43%)
General fatigue 2 (14%)
Chest discomfort 0 (0%)
Fainting 6 (43%)
Medications
Procainamide 1 (7%)
Mexiletine 4 (28%)
Pilsicainide 1 (7%)
Beta-blocker 7 (50%)
Bepridil 0 (0%)
Calcium channel blocker 1 (7%)
ACE inhibitor 0 (0%)
Sulfonylurea 1 (7%)
No drugs 5 (36%)
ACE  angiotensin-converting enzyme.
Table 4. Follow-Up Data of Patients With Un
Patients 1
Group Uppe
Echocardiogram
LVDd (mm) 60 (5
LVDs (mm) 45 (4
LVEF (%) 56 (5
Mitral regurgitation (degree) 2 (2
Chest radiogram
Cardiothoracic ratio (%) 57 (5
NYHA functional class 1 (1
%PVC (%) 19.4 (4
Medications Beta-blo
beprid
Values in the parentheses are data on admission.
LVDd  left ventricular end-diastolic dimension; LVDs  left
ejection fraction; NYHA  New York Heart Association; %PVCmproved LV function (4,5). However, these phenomena
ave never been documented in the large series of patients
ith PVC without underlying heart disease.
An RFA procedure for RVOT-PVC was performed in
5 patients, mostly females in this study. The reasons for a
uch higher prevalence of women may be that the study
opulation was limited to the patients with disabling PVC-
ssociated symptoms. This retrospective study provides
vidence in support of the concept that some of the patients
ith frequent RVOT-PVC, more than 20% per total heart
eats, without overt underlying structural heart disease were
ssociated with LV dilation (Figs. 1, 2B, 2C, and 2F),
hich was known to be a risk factor for LV dysfunction and
ongestive heart failure (8). Before RFA, LVEF, degree of
itral regurgitation, and NYHA functional class in these
atients were worse as compared to the patients with rare
VOT-PVC, 20% per total heart beats (Figs. 2A, 2D,
nd 3). These abnormalities were still present one day after
uccessful RFA. Furthermore, these parameters of the
atient with unsuccessful RFA with frequent PVC, but not
ith rare PVC, still deteriorated during follow-up. These
re Radiofrequency Catheter Ablation
Middle
(10%–20%; n  12)
Upper
(>20%; n  14)
7 (58%) 6 (43%)
1 (8%) 3 (21%)
1 (8%) 2 (14%)
3 (25%) 3 (21%)
0 (0%) 0 (0%)
2 (16%) 5 (36%)
1 (8%) 1 (7%)
5 (42%) 9 (64%)
0 (0%) 2 (14%)
1 (8%) 2 (14%)
1 (8%) 2 (14%)
1 (8%) 1 (7%)
6 (50%) 3 (21%)
essful Procedure
2 3
Middle Middle
49 (49) 45 (44)
31 (31) 30 (29)
67 (66) 67 (65)
0 (0) 0 (0)
44 (44) 47 (46)
1 (1) 1 (1)
9.5 (10.9) 10.0 (11.7)
Beta-blocker Beta-blocker,
mexiletineBefo
)succ
r
8)
3)
9)
)
7)
)
1.0)
cker,
ilventricular end-systolic dimension; LVEF  left ventricular
 frequency of premature ventricular complexes.
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LV Function Benefits of RFA of RVOT-PVC April 19, 2005:1259–65ndings may indicate that the frequent RVOT-PVC, more
han 20% per total heart beats, may be an important and
ndependent risk factor on progressing LV dysfunction and
eart failure. The findings of elevated serum brain natri-
retic peptide level and total heart rate (Table 2) before
FA in the upper group may also support the possibility of
eart failure progression. When the patients were divided
nto three groups according to the tertiles of the absolute
umber of PVC before RFA, the number of PVC more
han 20,000 beats per day was shown to be at risk (data not
hown). More importantly, ablating RVOT-PVC readily
roduced the improvement of these abnormalities without
dverse effects. Attenuation of progressive LV dilation has
roven to reduce the risk of cardiovascular events (8,10), and
FA is known to be safe and effective for the treatment of
rrhythmias as compared with medical therapy (7,14).
hus, RFA may be considered as the first choice of therapy
or patients with frequent RVOT-PVC with LV dilation.
Although the mechanism(s) of LV dilation in those with
VOT-PVC is not completely elucidated, several potential
echanisms can be raised. Most of the patients with
VOT-PVC demonstrate LBBB and inferior axis mor-
hology, and wide QRS complex generally 120 ms (1). It
as been reported that LBBB causes asynchronous myocar-
ial activation, which progresses into LV diastolic dysfunc-
ion and mitral regurgitation leading to decreased LV stroke
olume (18,19). Recent clinical trials revealed that perma-
ent RV apical pacing, which demonstrated LBBB pro-
oted heart failure progression (20–23). Furthermore, both
ermanent RV apical pacing and RVOT pacing could not
mprove quality of life or give other clinical benefits in
atients with permanent pacemaker implantation (24,25).
hus, LBBB-induced asynergic LV wall motion caused by
requent RVOT-PVC might be one of the important
actors of progressing LV dilation and reduced LVEF
bserved in this study. Moreover, it has been reported that
V contraction usually moves from the apical to the basal
ortion with LV apex rotation in accordance with squeezing
ffect (4) and torsional deformation (26,27) during sinus
hythm. Because the direction of LV contraction is reversed
uring RVOT-PVC, these effects may cause disruption and
urther progression of asynergic LV wall motion. Recent
linical studies reported that cardiac resynchronization re-
ulted in significant clinical improvements in patients who
ad chronic heart failure and wide QRS interval (28,29). In
iew of these findings, eliminating RVOT-PVC by RFA
ay be a subset of resynchronization therapy.
imitations of the study. Our study is limited by its
etrospective design and relatively short follow-up period.
erum brain natriuretic peptide concentration was not
valuated in all patients. Although the differences in LV
ilation, LVEF, degree of mitral regurgitation, and NYHA
unctional class observed in patients with frequent PVC
fter RFA were statistically significant, they were relatively
ild. Whether our results can safely be extrapolated to the
atients with much larger LV and reduced LVEF should beetermined in further studies. Recent case reports showed
hat a similar beneficial effect of RFA on LV function was
een in patients with a more severe form of heart failure
4,5), supporting our hypothesis.
onclusions. A subgroup of patients with frequent
20%) PVC demonstrated significantly enlarged LVDd,
educed LVEF, increased mitral regurgitation, and deteri-
rated NYHA functional class as compared to the subgroup
ith rare (20%) PVC. Furthermore, the ablation of these
rrhythmias was associated with the normalization of these
bnormalities without adverse effects. These findings sug-
est that RVOT-PVC may be a possible cause of LV
ysfunction and/or heart failure. Thus, the physicians
hould be aware of the condition when examining a patient
ith LV dilation and/or reduced LVEF in the presence of
requent RVOT-PVC because it may be at least one
mportant risk factor on progressing LV dysfunction and
eart failure. Radiofrequency catheter ablation may be
onsidered as the first choice of therapy for those patients.
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